Oscar Méndez-Lucio

Oscar Méndez-Lucio

Auto-generated profile, based on publicly available information

Oscar Méndez-Lucio

Recursion (United States)

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
OMOscar Méndez-Lucio
Oscar Méndez-Lucio
BBBenoit Baillif
Benoit Baillif
DCDjork-Arné Clevert
Djork-Arné Clevert
DRDavid Rouquié
David Rouquié
JWJoerg Wichard
Joerg Wichard
Finding new molecules with a desired biological activity is an extremely difficult task. In this context, artificial intelligence and generative models have been used for molecular de novo design and compound optimization. Herein, we report a generative model that bridges systems biology and molecular design, conditioning a generative adversarial network with transcriptomic data. By doing so, we can automatically design molecules that have a high probability to induce a desired transcriptomic profile. As long as the gene expression signature of the desired state is provided, this model is able to design active-like molecules for desired targets without any previous target annotation of the training compounds. Molecules designed by this model are more similar to active compounds than the ones identified by similarity of gene expression signatures. Overall, this method represents an alternative approach to bridge chemistry and biology in the long and difficult road of drug discovery.

2 December 2021 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
OMOscar Méndez-Lucio
Oscar Méndez-Lucio
MAMazen Ahmad
Mazen Ahmad
EREhecatl Antonio del Rio-Chanona
Ehecatl Antonio del Rio-Chanona
JWJörg Kurt Wegner
Jörg Kurt Wegner

1 January 2017 in Drug Discovery Today
Verified
Journal Article
Closed access
OMOscar Méndez-Lucio
Oscar Méndez-Lucio
JMJose Medina-Franco
Jose Medina-Franco

7 October 2014 in MedChemComm
Verified
Journal Article
Open access
PDF file
ICIsidro Cortés-Ciriano
Isidro Cortés-Ciriano
QAQurrat Ul Ain
Qurrat Ul Ain
VSVigneshwari Subramanian
Vigneshwari Subramanian
ELEelke B. Lenselink
Eelke B. Lenselink
OMOscar Méndez-Lucio
Oscar Méndez-Lucio
ABAndreas Bender
Andreas Bender
Proteochemometric (PCM) modelling is a computational method to model the bioactivity of multiple ligands against multiple related protein targets simultaneously. Hence it has been found to be particularly useful when exploring the selectivity and promiscuity of ligands on different proteins. In this review, we will firstly provide a brief introduction to the main concepts of PCM for readers new to the field. The next part focuses on recent technical advances, including the application of support vector machines (SVMs) using different kernel functions, random forests, Gaussian processes and collaborative filtering. The subsequent section will then describe some novel practical applications of PCM in the medicinal chemistry field, including studies on GPCRs, kinases, viral proteins (e.g. from HIV) and epigenetic targets such as histone deacetylases. Finally, we will conclude by summarizing novel developments in PCM, which we expect to gain further importance in the future. These developments include adding three-dimensional protein target information, application of PCM to the prediction of binding energies, and application of the concept in the fields of pharmacogenomics and toxicogenomics. This review is an update to a related publication in 2011 and it mainly focuses on developments in the field since then.

12 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
OMOscar Méndez-Lucio
Oscar Méndez-Lucio
CNChristos A. Nicolaou
Christos A. Nicolaou
BEBerton Earnshaw
Berton Earnshaw
Models that accurately predict properties based on chemical structure are valuable tools in the chemical sciences. However, for many properties, public and private training sets are typically small, making it difficult for models to generalize well outside of the training data. Recently, this lack of generalization has been mitigated by using self-supervised pretraining on large unlabeled datasets, followed by finetuning on smaller, labeled datasets. Inspired by these advances, we report MolE, a Transformer architecture adapted for molecular graphs together with a two-step pretraining strategy. The first step of pretraining is a self-supervised approach focused on learning chemical structures trained on ~842 million molecular graphs, and the second step is a massive multi-task approach to learn biological information. We show that finetuning models that were pretrained in this way perform better than the best published results on 10 of the 22 ADMET (absorption, distribution, metabolism, excretion and toxicity) tasks included in the Therapeutic Data Commons leaderboard (c. September 2023).

1 September 2013 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
RARodrigo Aguayo-Ortiz
Rodrigo Aguayo-Ortiz
OMOscar Méndez-Lucio
Oscar Méndez-Lucio
Antonio Romo-MancillasAntonio Romo-Mancillas
Antonio Romo-Mancillas
RCRafael Castillo
Rafael Castillo
LYLilián Yépez-Mulia
Lilián Yépez-Mulia
AHAlicia Hernández-Campos
Alicia Hernández-Campos